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Abstract
Background: Secretory phospholipase A2 group IIA (IIA PLA2) is a protein shown to be highly expressed in the
intestine of mammals. However, no study was reported in birds.
Results: Chicken intestinal group IIA phospholipase A2 (ChPLA2-IIA) was obtained after an acidic treatment (pH.3.0),
precipitation by ammonium sulphate, followed by sequential column chromatographies on Sephadex G-50 and
mono-S ion exchanger. The enzyme was found to be a monomeric protein with a molecular mass of around
14 kDa. The purified enzyme showed a substrate preference for phosphatidylethanolamine and
phosphatidylglycerol, and didn’t hydrolyse phosphatidylcholine. Under optimal assay conditions, in the presence of
10 mM NaTDC and 10 mM CaCl2, a specific activity of 160 U.mg
-1 for purified ChPLA2-IIA was measured using egg
yolk as substrate. The fifteen NH2-terminal amino acid residues of ChPLA2-IIA were sequenced and showed a close
homology with known intestinal secreted phospholipases A2. The gene encoding the mature ChPLA2-IIA was
cloned and sequenced. To further investigate structure-activity relationship, a 3D model of ChPLA2-IIA was built
using the human intestinal phospholipase A2 structure as template.
Conclusion: ChPLA2-IIA was purified to homogeneity using only two chromatographic colomns. Sequence analysis
of the cloned cDNA indicates that the enzyme is highly basic with a pI of 9.0 and has a high degree of homology
with mammalian intestinal PLA2-IIA.
Background
Phospholipases A2 (PLA2s) hydrolyse the sn-2 bond of
phospholipids resulting in the release of a fatty acid and
lysophospholipid. Mammalian PLA2s are classified in
three broad categories of secreted PLA2 (sPLA2)a n d
cytosolic PLA2s which are either calcium dependent as to
their catalytic activity, or calcium independent cytosolic
PLA2s [1]. Secreted PLA2s are small molecular size pro-
teins (14-19 kDa) with a rigid tertiary structure, having
five to eight disulfide bonds that probably confer resis-
tance to proteolysis and thermal denaturation [1,2] with
a highly conserved catalytic site and a Ca
2+-binding loop.
These secreted PLA2s were first detected in snake venom
pancreatic juice and in tissues [3]. Secreted PLA2sa r e
also expressed in a number of cell types and present in
various body fluids. They participate in the first line in
antimicrobial defence of the body against bacteria and
other pathogens. The extensive literature on sPLA2si n
inflammatory diseases has been reviewed [4-11].
The gene of pancreatic PLA2-IB was first isolated in
1986 [12] followed in 1989 by the cloning of non-pan-
creatic PLA2-IIA from rheumatoid arthritic synovial
fluid [13] and blood platelets [14]. Together with pan-
creatic PLA2-IB, the sPLA2-IIA are the best known and
biochemically characterized enzymes. Novel sPLA2 were
identified in the 90
th by screening nucleic acid data
bases. Up to now, eleven sPLA2s have been cloned: IB,
IIA, IIC, IID, IIE, IIF, III, V, X, and XIIA PLA2s together
with the XIIB PLA2-like protein devoid of catalytic
activity [1,15,16]. They express different catalytic and
binding properties to natural phospholipids [17,18].
Earlier studies have localized sPLA2-IIA in the intes-
tine [19,20] and in the synovial fluid of patients with
rheumatoid arthritis as well as sPLA2 released from pla-
telets [14,21]. The concentration levels of PLA2-IIA
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any medium, provided the original work is properly cited.increase in sera of patients suffering from severe acute
inflammatory diseases, such as sepsis and bacterial infec-
tions [22,23] and acute pancreatitis [24]. The sPLA2-IIA
was originally localized in Paneth cells of the rat intes-
tine [25,26] and later on in macrophages [27,28]. The
two above mentioned cell types are both involved in the
antibacterial response.
Later on it was demonstrated that the PLA2-IIA from
human and mouse, with high activity on phosphatidyl-
glycerol and bearing cationic properties (pI > 9.0), are
highly bactericidal against gram positive bacteria [29-33]
by perturbing the anionic bacterial cell wall [34]. The
bacteria digested by the intestinal PLA2 do not necessa-
rily have to be within the intestinal lumen. Some bac-
teria specifically invade the intestinal mucosa from the
lamina propria, as it has been postulated to occur in
Whipple’s disease [35]. The human PLA2-IIA enzyme
shows low affinity for zwitterionic interfaces, and in the
absence of interfacial binding mammalian membrane
hydrolysis is not possible [36].
With the growing interest in chicken diseases, such as
avian influenza, we recently focused on bird sPLA2 to
further gain some functional and pathological insights.
Ben Bacha et al. [37] have biochemically characterized an
a c t i v et h e r m os t a b l eP L A 2-IB from ostrich pancreas
(OPLA2). Another PLA2-IB was also purified from chicken
pancreas and biochemically characterized [38]. It was
therefore of interest to further study some biochemical
and structural properties of avian non-pancreatic PLA2 to
gain more insights into their mode of action on phospholi-
pids and to compare their properties with those of mam-
malian PLA2. We report here, the purification and some
biochemical properties of a secreted PLA2 from chicken
intestine (ChPLA2-IIA). This work reports also the cloning
of the corresponding bird PLA2 cDNA and the compari-
son of its deduced amino acid sequence with other known
mammalian PLA2. A molecular 3D model of ChPLA2-IIA
is also proposed to explain some biochemical differences
of ChPLA2-IIA with other intestinal and pancreatic PLA2.
Results and discussion
Determination of phospholipase activity
The PLA2 activity was measured titrimetrically at pH 9.0
and at 40°C with a pH-stat, under the standard assay con-
ditions as described previously [39], using egg yolk (0.5%
W/V) as substrate, in 30 ml of 150 mM NaCl, 10 mM
NaTDC and 10 mM CaCl2. The analysis of the purified
egg yolk phospholipids by thin layer chromatography
revealed the presence of two spots. The major one (90%)
corresponds to the phosphatidylcholine (PC, or lecithin)
and the second one (10%) phosphatidylethanolamine
(PE). These two phospholipids were separated by adsorp-
tion chromatography on a silica gel column. Elution was
performed using stepwise ratios of chloroform/methanol.
We incubated the purified PC or PE samples with
ChPLA2-IB or ChPLA2-IIA respectively and a thin layer
chromatography was performed as shown in Figure 1. As
expected, ChPLA2-IB hydrolyzes efficiently PC and PE
since the spots of these two phospholipids totally disap-
peared and a spot of free fatty acid appeared. In contrast,
ChPLA2-IIA didn’t hydrolyze PC even after a long incu-
bation period. Interestingly, PE was totally hydrolyzed by
ChPLA2-IIA similarly to what observed with ChPLA2-IB.
These analytical results clearly indicate that the hydroly-
tic activity of ChPLA2-IIA, measured with pH-stat using
egg yolk as substrate, is mainly due to the hydrolysis of
the PE fraction.
Purification of ChPLA2-IIA
ChPLA2-IIA was purified from the intestine mucosa
using an acidic treatment, ammonium sulfate precipita-
tion, followed by two chromatography steps on Sephadex
G-50, and Mono-S Sepharose according to the procedure
described in Material and Methods (Figure 2). The main
steps of the purification procedures and flow sheet are
summarized in Table 1. The specific activity of pure
ChPLA2-IIA reaches 160 U.mg
-1 when egg yolk was used
as substrate, at pH 9.0 and at 40°C, in the presence of 10
mM NaTDC, and 10 mM CaCl2. The ChPLA2-IIA purifi-
cation yield was about 10%.S D S - P A G Ea n a l y s i so ft h e
purified ChPLA2 IIA eluted from the Mono-S column
show that the enzyme exhibited one homogenous band
corresponding to an apparent molecular mass of about
14 kDa (Figure 2). The calculated molecular mass, using
the amino acid sequence is 13616Da. Furthermore, the
calculated isoelectric pH was equal to pH 9.01.
         5 1            2          3 4 6 7
Figure 1 Thin layer chromatography of PC and PE before or
after incubation with ChPLA2-IIA or ChPLA2-IB. After solvent
migration the silica plate was exposed to iodine vapor to reveal the
various spots. Lane (1), PC. Lane (2), PC incubated with PLA2 from
chicken pancreas (PLA2-IB) and showing a complete hydrolysis of
the PC. Lane (3), PC incubated with PLA2 from chicken intestine
(PLA2-IIA). Lane (4), PE. Lane (5), PE incubated with PLA2-IB and
showing a complete hydrolysis of the PE. Lane (6), PE incubated
with PLA2-IIA and showing a complete hydrolysis of the PE. Lane
(7), free fatty acid C 18:1.
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Figure 2 Purification of ChPLA2-IIA. (A) Gel filtration chromatography of intestinal ChPLA2-IIA on Sephadex G-50. The column (1.5 cm ×
34 cm) equilibrated in 20 mM Tris-HCl buffer pH 8.0 containing 20 mM CaCl2 and 2 mM benzamidine. Elution was performed with the same
buffer at a flow rate of 40 ml.h
-1 and 3 ml samples were collected. ChPLA2-IIA activity was measured as described in Material and methods
section using egg yolk emulsion as substrate. The pooled fractions containing the PLA2 activity were indicated by horizontal line. (B) Mono-S
Sepharose chromatography. The column (5 cm × 2 cm) was equilibrated with 20 mM Tris HCl buffer pH 8.0 containing 20 mM CaCl2 and 2 mM
benzamidine; and then washed with the same buffer containing 0.3 M NaCl. Linear salt gradient (0.3 to 1 M NaCl, dotted line) was applied to
the column; gradient chamber 75 ml; 2 ml fraction; flow rate, 40 ml/h. The pooled fractions containing the PLA2 activity were indicated by
horizontal line. SDS-PAGE (15%) analysis of pure ChPLA2-IIA was inserted in Figure 2B. Lane 1, molecular mass markers (MM); Lane 2, 15 μgo f
proteins obtained after Sephadex G-50 chromatography; Lane 3, 15 μg of purified ChPLA2-IIA, obtained after Mono-S chromatography.
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Ca
2+ dependence
It is well established that Ca
2+ is essential for both, cata-
lysis and enzyme binding to the substrate [40-42]. In
order to investigate the effect of Ca
2+ on ChPLA2-IIA
activity, we studied the variation of hydrolysis rates of
egg yolk phospholipids by pure ChPLA2-IIA in the pre-
sence of various Ca
2+ concentrations (Figure 3A). Our
results showed that no PLA2 activity can be detected in
the absence of Ca
2+ and in the presence of 10 mM
EDTA or EGTA. In the absence of calcium chelators,
the specific activity of purified ChPLA2 increases to
reach 160 U.mg
-1 at 10 mM CaCl2 (Figure 3A).
These observations corroborate previous findings with
porcine [20], rat [19], and human [14] intestinal PLA2.
We previously reported that pancreatic chicken PLA2-IB
requires only 4 mM of CaCl2 to reach its maximal activ-
ity (Figure 3A and [38]).
Bile salts dependence
Several studies have provided evidence that bile salts
are tensioactive agents ensuring in their micellar form,
the dispersion of the lipolytic products (of hydrolysis,)
[43,44]. Along the same line, De Haas et al. reported
that micellar forms of the substrate were hydrolysed at
a much higher rate than substrates molecularly dis-
persed by PLA2 [45]. In this study, we measured the
ChPLA2-IIA activity at pH 9.0 and at 40°C using egg
yolk as substrate in the presence of increasing concen-
trations of bile salts. As shown in Figure 3B, NaTDC
was required for ChPLA2-IIA activity. ChPLA2-IIA was
poorly active at concentrations lower than 2 mM of
NaTDC. This activity increases with increasing bile
salts concentration and the maximal PLA2 activity was
m e a s u r e di nt h ep r e s e n c eo f1 0m MN a T D C .I nc o n -
trast, we have presently shown, confirming our pre-
vious work, that pancreatic chicken PLA2-IB was
found to be active in the absence of NaTDC and its
optimal activity was found to be nearly independent of
NATDC (Figure 3B and [38]. One has to recall that in
the assay using egg yolk emulsion as substrate, the
pancreatic PLA2 hydrolyses both PC and PE whereas
the intestinal enzyme hydrolyses only PE.
Effect of temperature on ChPLA2-IIA activity and stability
Figure 4A shows that the maximal activity of ChPLA2-
IIA was measured at 40°C using egg yolk as substrate in
t h ep r e s e n c eo f1 0m MC a
2+ and 10 mM NaTDC.
Unlike pancreatic ChPLA2-IB [38] which is totally inac-
tivated at high temperature, the ChPLA2-IIA maintained
about 60% of its activity after 15 min of incubation at
60°C (Figure 4B). Comparable results were obtained
with mammalian intestinal PLA2 from various species
which show a good stability at high temperature [46,47].
Effects of pH on ChPLA2-IIA activity and stability
As shown in Figure 4C, the maximal activity of
ChPLA2-IIA was measured at pH 9.0 and at 40°C using
e g gy o l ka ss u b s t r a t ei nt h ep r e s e n c eo f1 0m MC a
2+
and 10 mM NaTDC. Similar results were obtained with
ChPLA2-IB and human intestinal PLA2-IIA. However,
the purified ChPLA2-IIA was found to be stable between
pH 3.0 and 10.0 (Figure 4D). In contrast to the ChPLA2-
IB, which was found to lose its activity when incubated
at pH lower than 5 [38], pure ChPLA2-IIA maintained
about 50% of its activity after 15 min of incubation at
pH 3.0 (see Figure 4D). It was also reported that porcine
[20] rat [19] and human [14] intestinal PLA2 are stable
at low pH values as compared to ChPLA2-IIA. Whereas,
some pancreatic PLA2-IB are very acid and thermo
stable [37,48].
N-terminal sequence of ChPLA2-IIA
The NH2 terminal sequencing of the ChPLA2-IIA
allowed unambiguously the identification of the first
fourteen residues of pure enzyme. Table 2 shows that the
N-terminal sequence of ChPLA2-IIA has identity at 80%
with mouse, 53% with human, and 53% with porcine
PLA2-IIA respectively. Pure ChPLA2-IIA exhibits a high
degree of homology with mouse intestinal PLA2-IIA.
Cloning and sequencing of the gene coding ChPLA2-IIA
The cDNA encoding ChPLA2-IIA was selectively ampli-
fied by RT-PCR from total mRNA extracted from
Table 1 Flow sheet of chicken intestinal phospholipase A2 purification
Purification Step Total Activity (U)
a Total Protein (mg)
b Yield (%) Specific activity (U/mg) Purification Factor
Extraction
(pH 8.5)
250 5520 100 0.045 1
Acidic treatment (pH3) 123 205.5 49 0.6 13.33
(NH4)2SO4
Precipitation
(60%)
108 108 43 1 22.22
Sephadex G-50 95 6.41 38 14.8 328.88
MonoS Sepharose 25 0.156 10 160 3555
a) 1 Unit: μmole of fatty acid released per min using egg yolk as substrate in the presence of 10 mM NaTDC and in the presence of 10 mM CaCl2.
b) Proteins were estimated by Bradford method [30]. The experiments were conducted in triplicate.
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The corresponding DNA was ligated into pET 21a(+)
vector and used for transformation into E. coli DH10B
cells. Several clones are selected and some of them con-
tained a recombinant plasmid with a 500 pb EcoRI/XhoI
insert. The cDNA sequencing, confirmed that the PCR
product corresponds to the gene encoding for the mature
ChPLA2-IIA (Figure 5). The deduced polypeptide
sequence of ChPLA2-IIA, corresponding to the mature
protein, comprises 123 amino acids. ChPLA2-IIA shares
45% of identity with human PLA2-IIA and 51% of iden-
tity with mouse PLA2-IIA. Residues of the catalytic diad
are conserved in ChPLA2-IIA. The 14 cystein residues
involved in disulfide bridges in all known PLA2 IIA are
also conserved in ChPLA2-IIA suggesting also the pre-
sence of 7 disulfide bridges in its 3D structure.
Homology modelling
To provide an insight into the biochemical properties,
the structure model of the ChPLA2-IIA was built, using
the 3D structure of the hPLA2 (PDB code: 1N28) as
template. These two proteins shares 45% amino acid
identity. The model of the ChPLA2-IIA was then
subjected to molecular mechanics optimization
using CHARMM27 force-field. Energy minimization
(geometry optimization) was performed until the gradi-
ent of 0.01 kcal/(Å.mol) was reached. The RMS devia-
tions involving a-carbons between the initial and the
optimized models was 0.95 Å. The Ramachandran plot
statistics of the final ChPLA2-IIA model and of the
hPLA2, determined using the PROCHECK program,
showed that 97.2%, and 100% of the residues were either
in the most favored or in the additional allowed regions,
respectively.
Overall 3D structure model of ChPLA2
As shown in Figure 6, the ChPLA2-IIA has a globular
shape with an a/b hydrolase fold stabilized by seven dis-
ulfide bridges similar to those present in all group IIA
sPLA2. The core structure consists of four a-helices
(aA: Ile2-Thr13; aB: Ala17-Gly22, aC: Ala38-Ser55 and
aD: Ser81-Thr103) and two short anti-parallel b-strands
(b1:P h e 6 7 - L y s 7 0a n db2 : Gln73-Cys76) located
between helix aCa n daD. The catalytic Ca
2+ ion is
coordinated via oxygen atoms of His26 and Gly28 which
belong to the Ca
2+-binding loop and the two oxygen
atoms, Oδ1 and Oδ2o fA s p 4 7 .T h eC h P L A 2-IIA model
showed that (O) Gly22, (O) Gly24, (O) Tyr111 and
(Oδ1) Asn113 are located at an interaction distance of
2.2 Å with a second Ca
2+ ion. However these residues
correspond in ChPLA2-IB to Asp24, Gly26, Leu118 and
Lys120, respectively. No fourth amino acid was found in
a favorable position to interact with this ion in ChPLA2-
IB due to the substitution of Asn113 (Oδ1) (in ChPLA2-
IIA) by Lys120 (in ChPLA2-IB). This second Ca
2+ ion
may help the stabilization of the C-terminal (Tyr111
and Asn113) with the helix aB (Gly22, and Gly24) and
furthermore the Ca
2+-binding loop.
Although ChPLA2-IIA and ChPLA2-IB share seven
disulfide bridges, only six of them are structurally con-
served. In ChPLA2-IB, the disulfide bridge between
Cys11 and Cys77 may stabilize the N-terminal a-helix
aA with one of the two short strands of an anti-parallel
b-sheet (b-wing) (b2 ) .H o w e v e r ,i nC h P L A 2-IIA, one
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Figure 3 Effect of Ca
2+ and NaTDC on ChPLA2-IB and ChPLA2-
IIA activities. (A) Effect of Ca
2+ concentration on ChPLA2-IIA (black
circle) and ChPLA2-IB (white circle) activities. Enzyme activity was
measured at various concentrations of Ca
2+ using egg yolk
emulsion as substrate at pH 9.0 and at 40°C in the presence of 10
mM NaTDC. The star indicates the phospholipase activity measured
in the absence of CaCl2 and in the presence of 10 mM EDTA or
EGTA. (B) Effect of increasing concentration of bile salts (NaTDC) on
ChPLA2-IIA (black circle) and ChPLA2-IB (white circle) activities. PLA2
activity was measured using egg yolk emulsion as substrate at pH
9.0 and at 40°C in the presence of 10 mM Ca
2+.
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Page 5 of 12new disulfide bridge is formed between Cys48 (belong to
helix aC) and C-terminal Cys123.
To get more insight on the stabilization effect of the sec-
ond calcium ion, molecular dynamics simulations were car-
ried out (1 ns) at 330°K for the minimized models of the
ChPLA2-IIA in the presence and the absence of this ion.
The RMSD value for the backbone atoms was used to
understand the response behavior. The 2D-RMSD plot,
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Figure 4 Effect of temperature and pH on ChPLA2-IB and ChPLA2-IIA. Effects of temperature (A, B) and pH (C, D) on ChPLA2-IIA (black
circle) and ChPLA2-IB (white circle) activities (A, C) and stability (B, D). PLA2 were tested for activity at various temperatures (A) and pH (C) as
described in material and methods. To study the stability of PLA2, 1 mg.ml
-1 of each enzyme was incubated during 30 min at various
temperatures (B) and pH (D). Residual PLA2 activity was measured using egg yolk as substrate in the presence of 10 mM Ca
2+ and 10 mM
NaTDC. For temperature stability studies, enzymes were incubated in 10 mM Tris (pH 8.0) and 10 mM CaCl2. For pH stability studies, Tris buffer
was replaced by the appropriate buffer for the pH range.
Table 2 Alignment of the N-terminal amino-acid
sequence of ChPLA2-IIA with mouse, human and porcine
intestinal phospholipases
Chicken: N IAQ F GIMIK EKTGK (present work)
Mouse: N IAQ F GEMIR LKTGK [19]
Human: N LVN F HRMIK LTTGK [14]
Porcine: D LLN F RKMIK LKTGK [20]
Identical aminoacids are in bold, and homologous aminoacids are in italic.
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Page 6 of 12where the root mean square deviation of every conformation
to all others of a simulation is shown, demonstrated that the
conformational space sampled by ChPLA2-IIA in the simu-
lations was larger in the absence of Ca
2+ ion (Figure 6).
Docking
T h et o t a la c c e s s i b l es u r f a c ea r e ao ft h eC h P L A 2-IIA and
ChPLA2-IB were 6591 and 6522 Å
2, respectively. The posi-
tive charged surface of the ChPLA2-IIA (876 Å
2, 12.6%)
was higher than that of ChPLA2-IB (440 Å
2,6 . 7 % ) .
Furthermore, the negative charged surfaces of the
ChPLA2-IIA and ChPLA2-IB were 69 Å
2, (1%) and 399 Å
2,
(6.1%), respectively.
Analysis of PLA2 structures bound to a substrate can
help in understanding the interaction mode of the sub-
strate once located in the catalytic pocket.
The docking of the substrate (PC, PE or PG) to the
ChPLA2-IIA and the ChPLA2-IB protein was performed
using the Molegro Virtual Docker v.4.0.2 software,
respectively (data not shown). According to the protein-
substrate complexes, 13 or 12 residues are in van der vaals
contact with the substrate in the case the ChPLA2-IIA and
ChPLA2-IB, respectively. In the case of the ChPLA2-IIA,
the total interaction energy between the protein and the
target substrate is -134.8, -128.4 and -137,9 kJ/mol for PC,
PE or PG respectively. In the case of the ChPLA2-IB, the
total interaction energy is -183.8, -142.3 and -192.2 kJ/mol
for PC, PE or PG respectively. These above mentioned
interaction energy may help to explain the lack of catalytic
activity of the ChPLA2-IIA on PC as substrate.
Materials and methods
Materials
Benzamidine was from Fluka (Buchs, Switzerland),
bovine serum albumine (BSA), anhydrous magnesium
sulfate, anhydrous sodium sulfate, potassium chloride,
sodium chloride, taurodeoxycholic acid sodium salt
(NaTDC) and PC were purchased from Sigma Chemical
1   atg aag ctc ctg gtg ctc ctc gtc tgc ctt gca gtg ctg gcc ccc  45
1 M   K   L   L   V   L   L   V   C   L   A   V   L   A   P 15
46   gcg ggc tgc aac ata gct cag ttt ggt atc atg att aag gag aag  90
16 A   G   C N   I   A   Q   F   G   I   M   I   K E   K   30
91   act ggg aag cct gcg ctg tcc tac aat ggc tat ggc tgc cac tgc 135
31    T   G   K   P   A   L   S   Y   N   G   Y   G   C   H   C   45
136  ggc ctt ggg gga tcc aag tac ccg gtg gat gcg acc gac tgg tgc 180
46    G   L   G   G   S   K   Y   P   V   D   A   T   D   W C 60
181  tgc cat gcc cac gac tgc tgc tac aag agg ttg tca tcc gtg acc 225
61 C   H   A   H   D   C   C Y   K   R   L   S   S   V   T   75
226  tgc gtt ccc cac ctt gcc act tac aaa ttc tcc atc aag aga ggc 270
76    C   V   P   H   L   A   T   Y   K   F   S   I   K   R   G   90
271  cag atc aca tgc gga tct gga agt tca tgc caa aga gct gct tgc 315
91    Q   I   T   C   G   S   G   S   S   C   Q   R   A   A   C  105
316  gag tgt gac aag aag gca gca gag tgt ttc aag agg aac ctc aga 360
106   E   C   D   K   K   A   A   E   C   F   K   R   N   L   R  120
361  act ttc aac aaa agc tac cag aat tat cta aac ttc aag tgc aag 405
121   T   F   N   K   S   Y   Q   N   Y   L   N   F   K   C   K  135
406  ggc tca cgt ccc tct tgc tag 426
136   G   S   R   P   S   C
Figure 5 Nucleotide sequence of the cDNA of ChPLA2-IIA and the deduced amino acid sequence. Sequencing was performed in triplicate
with three independent PCRs. The amino acid sequence obtained by N-terminal amino-acid sequence of the pure ChPLA2-IIA is shown in italic.
M1-C18 in bold, signal peptide; Y41-G49 in square, Ca
2+ loop; and H64-D65 with stars, active site.
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Figure 6 3D modelling structure of ChPLA2-IIA. (A) Cartoon representation the 3D model of the mature ChPLA2-IIA. Secondary structure
elements labels are indicated. a-helices and b-strands are colored in red and yellow, respectively. The catalytic network and the Ca
2+-binding
residues are indicated and shown as sticks. The disulfide-bridges are shown in yellow. (B) Cartoon representation of the ChPLA2-IIA structure
showing amino acids (represented by sticks) interacting with the substrate (PG). The substrate is indicated as a stick representation. The Ca
2+
ions are represented by a blue spheres. This figure was generated using the PYMOL software.
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Page 8 of 12(St. Louis, MO, USA); acrylamide and bis-acrylamide
electrophoresis grade were from BDH (Poole, UK), mar-
ker proteins and supports of chromatography used for
phospholipase purification: Sephadex G-50, MonoS
sepharose, were from Pharmacia (Uppsala, Sweden);
protein sequencer Procise 492 equipped with 140 C
HPLC system provided from Applied Biosystems
(Roissy, France); pH-stat was from Metrohm (Herisau,
Switzerland).
All enzymes and reagents used in DNA manipulations
were from Promega and Invitrogen (Paris, France). Oli-
gonuclotides were synthesized by Invitrogen. E. coli
strain DH10B was used as cloning host for the gene
part encoding the mature phospholipase. PCR products
were purified using the Wizard PCR Preps DNA purifi-
cation System (Promega).
Thin-layer Silica Gel 60 plates (10 × 20 cm from
Merck) were used for the separation of lipids. Lipid
standards (a-L-oleic acid C 18:1) and silica gel 60 pow-
ders (70-230) were from Sigma-Aldrich (Steinheim,
Germany). All solvents with HPLC grade were pur-
chased from SDS (Peypin, France).
Lipid extraction, separation and analysis
Ten micrograms of purified ChPLA2-IB and purified
ChPLA2-IIA were incubated respectively with 25 μMo f
pure phosphatidylcholine (PC) and phosphatidylethanol
(PE) dispersion in 1 ml buffer (10 mM Tris HCl, 10 mM
NaTDC and 10 mM CaCl2) at 37°C for 10 minutes. Lipo-
lysis was stopped by adding 200 μl of 1 M HCL and mix-
ing vigorously with 5 ml of chloroform/methanol mixture
(2:1, v/v) in a 15 ml glass tube with a Teflon-lined screw
cap. Lipids were immediately extracted as follows: after
separation phases, the lower organic phase was transferred
to a 15-ml test tube and dried over anhydrous magnesium
sulphate. Once MgSO4 had precipitated, the clear organic
phase was removed by centrifugation and stored at -20°C
before TLC analysis.
To separate lipid classes, 1 to 50 μl of lipid extracts or
lipid standards at known concentrations were first
spotted onto a thin-layer silica plate. The elution of the
lipids was then performed in one step with a chloro-
form/methanol/water (65/25/4, v/v/v) solvent mixture.
Following chromatography, the plates were dried at
room temperature for 10 min then immediately placed
in the iodine.
Enzyme samples
The intestine from chicken was collected from a local
slaughterhouse (Sfax, Tunisia). Immediately after slaugh-
ter, the most distal intestine was opened on a glass plate
on ice. The content of each ileal segment was flushed
twice with 100 ml of 0.15 M NaCl. Adherent mesentery
was removed as completely as possible.
Purification of ChPLA2-IIA
Fifty grams of chicken intestine mucosa were suspended
in 50 ml of buffer A (0.01 M Tris-HCl pH 8, 0.15 M
NaCl, 0.02 M CaCl2 and 4 mM Benzamidine), and
ground mechanically twice for 30 s at room temperature
using the Waring Blendor system. Then, the mixture
was stirred in a cold room for 1 h and centrifuged dur-
ing 30 min at 12.000 rpm. The total PLA2 intestine
activity obtained was 250 U.
Acidic treatment
To inactivate proteins from the pancreatic juice and
secreted into the intestine, the supernatant was brought
to pH 3.0 by adding 6 N HCl under gentle stirring at 0°C.
Insoluble denatured proteins were removed by centrifu-
gation during 30 min at 12.000 g and the clear superna-
tant was adjusted to pH 8.0 with 4 N NaOH. The
recovery of PLA2 activity was of about 50%.
Ammonium sulphate precipitation
The supernatant (55 ml, 123 U) was brought to 60%
saturation with solid ammonium sulphate under stirring
conditions and maintained during 45 min at 4°C. After
centrifugation for 30 min at 12.000 g and at 4°C, the
precipitated PLA2 was resuspended in 2 ml of buffer A
containing 2 mM benzamidine. Insoluble material was
removed by centrifugation for 10 min at 24.000 g. The
recovery of PLA2 activity was about 45%.
Filtration on Sephadex G-50
The sample containing PLA2 activity (4 ml, 108 U) was
loaded on a column of sephadex G-50 (34 cm × 1.5 cm)
equilibrated with buffer B (20 mM Tris-HCl, pH 8 and
20 mM CaCl2). Elution of proteins was performed with
t h es a m eb u f f e ra t4 0m l . h
-1. The fractions containing
the PLA2 activity eluted between 1.5 and 1.8 void
volumes were pooled (Figure 2A).
Cation exchange chromatography
The pooled fractions of Sephadex G-50 column containing
PLA2 activity were poured into a Mono-S column (5 cm ×
2 cm) equilibrated with buffer B. Under these conditions,
the enzyme is adsorbed to the anionic support and the col-
umn was washed with 60 ml of the same buffer containing
0.3 M NaCl. ChPLA2-IIA was eluted by a linear salt gradi-
ent (0.3-1 M) NaCl as shown in Figure 2B.
Analytical methods
Protein concentration was determined as described by
Bradford et al. [49] using BSA as reference.
Analytical polyacrylamide gel electrophoresis of
proteins in the presence of sodium dodecyl sulfate
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Page 9 of 12(SDS-PAGE) was performed by the method of Laemmli
[50]. The proteins were stained with Coomassie brilliant
blue.
Amino acid sequencing
The N-terminal sequence was determined by automated
Edman’s degradation, using an Applied Biosystems Protein
Sequencer Procise 492 equipped with 140C HPLC system.
Bacterial starins, plasmids and media
E. coli strain DH10B was used as cloning host for the
gene part encoding for the mature PLA2. E. coli strain
was grown in Luria-Bertani medium, supplemented with
100 μg.ml
-1 ampicilline whenever plasmid maintenance
was required. The plasmid pET21a(+) (Novagen) was
used as cloning vector.
cDNA synthesis and amplification
Total mRNAs were isolated from chicken intestine using
the single step guanidine isothiocyanate/phenol/chloro-
form isolation method as described by Chomczynski and
Sacchi [51]. ChPLA2-IIA cDNA was obtained from total
m R N A sb yt h er e v e r s et r a n s c r i p t i o np r o c e d u r e( P r o -
mega). First strand cDNAs were prepared using 10 μgo f
total mRNAs as template (heat-denaturated for 5 min at
70°C,) 200 U MMLV reverse transcriptase (Invitrogen),
20 pmol of each deoxynucleoside triphosphate, and 20
pmol of each primer: forward primer, 5’- GAA TTC
A T GA A GC T CCT GG T GC T CC TC- 3 ’ and reverse
primer, 5’- CT C GAG CTA GCA AGA GGG ACG TGA
GCC -3’. The N-terminal primer was predicted, from the
N-terminal sequence of the ChPLA2;h o w e v e rt h e
C-terminal primer was deduced from the genome of Gal-
lus gallus (GenBank accession number: XP 424364).
Reverse transcription was carried out in a total reaction
volume of 20 μl for 5 min at room temperature and
60 min at 42°C. The cDNA/RNA heteroduplex was then
denaturated at 70°C for 15 min and cooled on ice.
Cloning of the mature PLA2 gene
Amplification of the specific ChPLA2-IIA cDNA was
carried out by PCR using the single strand cDNAs as
template with the forward and reverse primers pre-
viously described. PCR was performed in a 0.2 ml
Eppendorf tube with a Gene Amp
® PCR System 2700.
The PCR mixture contained 20 pmol of both primers,
20 pmol of each deoxynucleoside triphosphate, 5 U pfx
polymerase and polymerisation buffer in final volume of
100 μl. The single strand cDNAs were directly used as
template. The thermal profile involved 35 cycles of
denaturation at 94°C for 1 min, primer annealing at 60°
C for 1 min, and extension at 72°C for 3 min. The PCR
product (500 pb) was isolated and ligated into the EcoRI
and XhoI linearised and dephosphorylated pET21a(+)
vector, according to the manufacturer’sp r o t o c o l( P r o -
mega). Protoplasts of E. coli DH10B were transformed
with the ligation mixture. The resulting recombinant
plasmid was named pChPLA2. The presence of the
appropriated insert was verified by restriction analysis.
DNA sequences were elucidated by the dideoxynucleo-
tide chain termination method according to a cycle
sequencing protocol using thermosequenase (Amersham
Pharmacia Biotech). The sequencing reactions were
analysed with the DNA sequencer ABI PRISM 3100/
3100-Avant Genetic Analyser (California, USA). It was
performed three times, using the recombinant vector
pChPLA2 as template with T7 promoter primer and the
T7 reverse primer (Invitrogen).
Software for infrastructure
The sequence alignment was performed with BioEdit
Version 4.8.4 software. The Molecular Operating Envir-
onment 2008.10 (MOE) software was used for homology
modelling, molecular dynamics and structures visualiza-
tion. Models were stereochemically evaluated by the
program PROCHECK. The Visualization was performed
with PyMol version 0.99beta06. Figures were generated
by PyMol program.
Homology Modelling
The 3-D coordinates of the human group IIA secreted
PLA2 (hPLA2) (PDB code: 1N28) was extracted from the
Protein Data Bank http://www.rcsb.org. The hPLA2
structure was used as template to build a model of the
ChPLA2-IIA by using the structure-modelling program
Molecular Operating Environment 2008.10. The model
was then subjected to molecular mechanics optimization
using CHARMM27 force field, until a gradient of 0.01
kcal/(Å.mol) was reached.
Docking
The 1,2-dioctylcarbamoylglycero-3-O-phosphatidylcholine
(PC), 1,2-dioctylcarbamoylglycero-3-O-phosphatidyletha-
nolamine (PE) and 1,2-dioctylcarbamoylglycero-3-O-phos-
phatidylglycerol (PG) were modelled by the Molecular
Operating Environment 2008.10 (MOE) software using a
Simplified Molecular Input Line Entry Specification
(SMILES). The Molegro Virtual Docker v.4.0.2 software
was used for docking substrates, PC, PE or PG to the
ChPLA2-IIA and the ChPLA2-IB protein, respectively.
The potential binding sites (also referred to as cavities
or active sites) was being identified using the built-in
cavity detection algorithm, molecular surface with 0.5 Å
grid resolutions and 1.2 Å Probe size.
After preparation of the protein and the ligand, the
docking was performed using MolDock Score function,
MolDock SE search algorithm, 10 runs, energy minimi-
zation and optimize H-Bonds after docking, 2500
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Page 10 of 12iterations and 500 steps Simplex Evolution to generate
the best five poses scores which were visually analyzed.
Only one of these poses correctly bind to the active site
with a high score was used. The protein-substrate com-
plex was then subjected to molecular mechanics optimi-
zation using CHARMM27 force field as described
previously. The Score of the final protein-substrate com-
plex was evaluated using the total interaction energy
between the active site and the substrate.
Statistical analysis
All the results in figures and text are the average of at
least three replicate experiments. They were statistically
analyzed with SPSS software (version 100), using the
Duncan test performed after analysis of variance
(ANOVA).
Abbreviation
PLA2: phospholipase A2; sPLA2: secreted PLA2; ChPLA2-IB: Group IB chicken
pancreatic PLA2; ChPLA2-IIA : Group IIA chicken intestinal PLA2; hPLA2-IIA:
Group IIA human PLA2; NaTDC: taurodeoxycholic acid sodium salt; PC:
phosphtidylcholine; PE: phosphatidylethanolamine; TLC: thin layer
chromatography; ns: nanosecond. MMLV: Moloney murine leukemia virus.
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